Monday, 27 May 2019

Roche's Tecentriq extends progression-free survival in TNBC

22 October 2018 | News

TNBC, comprising 15% of all breast cancer cases, is more aggressive and treatment-resistant since the cancer does not express receptors for targeted therapies.

Singapore - Results from a Phase 3 clinical trial, IMpassion130, evaluating Roche unit Genentech's TECENTRIQ (atezolizumab) plus Celgene's ABRAXANE (nab-paclitaxel) in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) showed a treatment effect. The data were presented at ESMO in Munich.

Patients receiving the combination showed median progression-free survival (PFS) of 7.2 months compared to 5.5 months for ABRAXANE alone. The separation was statistically significant.

In a subgroup of PD-L1-positive patients, median PFS also favored the combination, 7.5 months versus 5.0 months.

Median overall survival (OS) favored the combo (21.3 months versus 17.6 months) in the intent-to-treat population but the separation was not statistically valid (p=0.0840). The combo extended OS 9.5 months In the PD-L1-positive population.

Development is ongoing.

TNBC, comprising 15% of all breast cancer cases, is more aggressive and treatment-resistant since the cancer does not express receptors for targeted therapies.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

 

Survey Box

Will stem cell therapy market witness highest growth in Asia by 2020?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls